Product logins

Find logins to all Clarivate products below.


Pulmonary Hypertension | Disease Landscape and Forecast | G7 | 2018

Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable, driven by the premium price that may be charged for PH agents. Commercial interest in PH is high as a result of recent and significant advances in the understanding of its etiology and pathophysiology and the emergence of new therapies to treat the disease.

Geographies:

United States, EU5, Japan

Key Drugs Covered:

Uptravi, Orenitram, Adempas, Opsumit, Adcirca, Tracleer, Revatio, Letairis/Volibris, Remodulin, Flolan, Veletri, Tyvaso, Ventavis, Beraprost, ralinepag, esuberaprost, bardoxolone methyl, inhaled dry powder treprostinil, INOpulse

Key Companies Mentioned:

Actelion · United Therapeutics · Bayer Healthcare · GlaxoSmithKline · Gilead Sciences · Pfizer · Arena Pharmaceuticals · Mannkind Corporation · Bellerophon Therapeutics · Liquidia Technologies · Reata Pharmaceuticals

Related Market Assessment Reports

Report
Pulmonary Hypertension – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pulmonary Arterial Hypertension (US)
Pulmonary arterial hypertension (PAH) is a rare and life-threatening disorder characterized by high blood pressure in the arteries of the lungs. The progressive condition is associated with…
Report
Pulmonary Hypertension – Landscape & Forecast – Disease Landscape & Forecast (G7)
Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the rarity of PH, the potential commercial opportunities for drugs approved…
Report
Pulmonary Hypertension | Disease Landscape & Forecast | G7 | 2024
Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the rarity of PH, the potential commercial opportunities for drugs approved for…
Report
Pulmonary Arterial Hypertension | Treatment Algorithms: Claims Data Analysis | US | 2024
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable…
Report
Pulmonary Hypertension – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Pulmonary hypertension disease patient populations, covering 171…